Novogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.10.24	Kazia Announces Positive Phase 1 Data For Concurrent Paxalisib, Radiation Therapy In Brain Tumor (RTTNews)
10.07.24	Kazia: Paxalisib Phase II/III Data Shows Improvement In Overall Survival (RTTNews)
06.12.23	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering (PR Newswire)
01.12.23	Kazia Therapeutics Announces Registered Direct Offering - Quick Facts (RTTNews)
01.12.23	Kazia Therapeutics Announces $2 Million Registered Direct Offering (PR Newswire)
29.11.23	Kazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncology (RTTNews)
29.11.23	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY (PR Newswire)
21.11.23	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire)
20.11.23	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire)
15.11.23	KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING (PR Newswire)
10.11.23	KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA (PR Newswire)
01.11.23	Kazia Provides Preliminary Update From Phase 2 Study Of Paxalisib In Primary CNS Lymphoma; Stock Up (RTTNews)
01.11.23	KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA (PR Newswire)
23.10.23	KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY (PR Newswire)
11.10.23	Kazia announces voluntary delisting from ASX (PR Newswire)
05.10.23	KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS (PR Newswire)
29.09.23	KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire)
06.07.23	KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY (PR Newswire)
08.06.23	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
25.05.23	KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT (PR Newswire)
14.04.23	KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (PR Newswire)
04.04.23	KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING (PR Newswire)
16.01.23	KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS (PR Newswire)
15.12.22	KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING (PR Newswire)
12.12.22	KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION (PR Newswire)
01.12.22	COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL (PR Newswire)
09.11.22	KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING (PR Newswire)
27.10.22	KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA (PR Newswire)
06.10.22	PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY (PR Newswire)
09.09.22	KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE (PR Newswire)
08.09.22	KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO (PR Newswire)
05.08.22	Kazia Reports Promising Interim Data From Phase I Trial Of Paxalisib (RTTNews)
05.08.22	KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES (PR Newswire)
12.07.22	KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER (PR Newswire)
06.07.22	FDA Awards Rare Pediatric Disease Designation To Kazia's Paxalisib For Childhood Brain Cancer (RTTNews)
06.07.22	Pre-market Movers: KRNT, GATO, BGXX, BHIL, SANA… (RTTNews)
06.07.22	US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
24.06.22	Pre-market Movers: TBLT, ZEN, BHAT, GROV, KZIA… (RTTNews)
17.06.22	FDA Awards Orphan Drug Designation To Kazia's Paxalisib For Rare Form Of Childhood Brain Cancer (RTTNews)
17.06.22	US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER (PR Newswire)
13.06.22	POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING (PR Newswire)
07.06.22	PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT (PR Newswire)
03.06.22	Kazia Therapeutics Reports Final Data From Phase II Study Of Paxalisib - Quick Facts (RTTNews)
03.06.22	KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE (PR Newswire)
31.05.22	GBM AGILE OPENS TO PAXALISIB IN EUROPE (PR Newswire)
23.05.22	KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO (PR Newswire)
17.05.22	KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE (PR Newswire)
29.04.22	KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO (PR Newswire)
08.04.22	KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS (PR Newswire)
08.04.22	TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’258.50	2.48 %	K V
Sonova Hldg	311.20	2.37 %	K V
Novartis	93.43	2.04 %	K V
Roche Hldg G	255.10	1.59 %	K V
Geberit	524.80	1.59 %	K V
Swiss Life Hldg	732.20	0.69 %	K V
UBS Group	28.26	0.43 %	K V
Swisscom	507.50	0.40 %	K V
Nestle	76.16	0.26 %	K V
Kuehne+Nagel Int	208.10	0.05 %	K V

Nachrichten zu Novogen Limited (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten